Tesaro Inc. (NASDAQ:TSRO) fell 1.7% during trading on Wednesday . The company traded as low as $93.67 and last traded at $94.02, with a volume of 225,404 shares traded. The stock had previously closed at $95.60.

A number of research firms have commented on TSRO. Leerink Swann lifted their target price on shares of Tesaro from $65.00 to $95.00 and gave the stock an “outperform” rating in a research report on Thursday, June 30th. Mizuho reaffirmed a “buy” rating and issued a $67.00 target price on shares of Tesaro in a research report on Wednesday, April 6th. Robert W. Baird began coverage on shares of Tesaro in a research report on Monday, July 18th. They issued an “outperform” rating and a $105.00 target price for the company. FBR & Co reaffirmed a “buy” rating and issued a $65.00 target price on shares of Tesaro in a research report on Friday, May 6th. Finally, Credit Suisse Group AG began coverage on shares of Tesaro in a research report on Friday, May 13th. They issued an “outperform” rating and a $56.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $76.50.

The stock’s market capitalization is $4.36 billion. The firm has a 50-day moving average of $75.73 and a 200 day moving average of $50.47.

Tesaro (NASDAQ:TSRO) last posted its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.22) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.69) by $0.53. The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $2.48 million. During the same period last year, the firm earned ($1.30) earnings per share. On average, analysts expect that Tesaro Inc. will post ($7.16) earnings per share for the current fiscal year.

In related news, VP Edward C. English sold 7,000 shares of the stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $40.75, for a total transaction of $285,250.00. Following the completion of the sale, the vice president now owns 3,500 shares of the company’s stock, valued at $142,625. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Jeffrey H. Hanke sold 12,500 shares of the stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $74.35, for a total transaction of $929,375.00. Following the sale, the vice president now directly owns 12,500 shares of the company’s stock, valued at approximately $929,375. The disclosure for this sale can be found here.

A number of large investors have recently bought and sold shares of TSRO. Jennison Associates LLC boosted its stake in Tesaro by 157.5% in the fourth quarter. Jennison Associates LLC now owns 938,461 shares of the biopharmaceutical company’s stock worth $49,100,000 after buying an additional 574,041 shares during the last quarter. Whittier Trust Co. boosted its position in Tesaro by 1.1% in the fourth quarter. Whittier Trust Co. now owns 20,945 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 220 shares in the last quarter. Bank of Montreal Can boosted its position in Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock worth $1,275,000 after buying an additional 24,119 shares in the last quarter. Mutual of America Capital Management LLC boosted its position in Tesaro by 95.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 39,520 shares of the biopharmaceutical company’s stock worth $2,068,000 after buying an additional 19,320 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 1,915 shares in the last quarter.

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.